Solid Tumour Molecular Testing
Solid tumour testing examines selected molecular changes in tumour tissue. Depending on the clinical question, results may support diagnosis, tumour classification, treatment planning, or clinical-trial assessment.
Available Testing Approaches
- Next-generation sequencing (NGS): Analyses multiple genes for selected DNA or RNA variants in a single assay.
- Fluorescence in situ hybridisation (FISH): Detects selected amplifications, deletions, or rearrangements.
- PCR-based testing: Provides targeted analysis for specific variants or fusions.
- Immunohistochemistry (IHC): Assesses protein expression and supports pathological classification.
Choosing the Right Test
The appropriate test depends on the tumour type, tissue available, prior results, treatment question, and current clinical guidance. A pathologist or oncologist should select the assay and interpret the result in context.
Specimen and Limitations
Testing commonly uses formalin-fixed, paraffin-embedded tissue. Tumour content, fixation, nucleic-acid quality, and panel coverage can affect whether a result is reportable. A negative result does not exclude changes outside the assay’s scope.
Testing at Jaipur Molecular Lab
Contact our team with the diagnosis and clinical question to confirm the available panel, tissue requirements, and reporting timeline.
This information is for general education and does not replace medical advice. Test selection and interpretation should be discussed with the treating clinician and pathologist.